BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LX4211 tablet: Phase I data

A Phase I trial in 12 patients showed that 2 doses of 150 mg solid oral LX4211 significantly increased total glucagon-like peptide-1 (GLP-1), active GLP-1 and peptide YY (PYY) from baseline (p=0.001, p=0.032 and p=0.004, respectively). Single doses of LX4211 also rapidly and significantly improved post-prandial glucose (PPG) and fasting plasma glucose (FPG)....

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >